FeesSafety
Pluang+

Rosemont Pharmaceuticals to acquire Aytu BioPharma for $2.70/share to boost US CNS drug portfolio.

Company Fundamentals
16 Nov 2026, 23:11 WIB
GlobeNewsWire
View Source
Bullish
Rosemont Pharmaceuticals to acquire Aytu BioPharma for $2.70/share to boost US CNS drug portfolio.

Rosemont Pharmaceuticals announced a definitive agreement to acquire Aytu BioPharma for $2.70 per share in cash, representing a 41.1% premium. This acquisition will enhance Rosemont's US presence by adding Aytu's established ADHD and emerging major depressive disorder treatments, along with a strong commercial platform. The deal is expected to close in late December 2026, pending usual conditions. The merger aims to accelerate growth and expand Rosemont's reach in the specialty pharmaceutical market, combining complementary portfolios and expertise.

Rosemont Pharmaceuticals' acquisition of Aytu BioPharma provides context for the health sector's performance on Pluang. For readers following health stocks, 31 of 150 priced US health-sector stocks rose while 118 fell. Notable movers include Summit Therapeutics Inc (USD 11.68, -17.46%), Ginkgo Bioworks Holdings Inc (USD 8.50, -11.55%), and Cassava Sciences Inc (USD 0.47, +10.56%). This data is as of Nov 17, 2026 03:31 WIB.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App